These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21809992)

  • 41. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients.
    Sornmayura P; Rerkamnuaychoke B; Jinawath A; Euanorasetr C
    J Med Assoc Thai; 2012 Jan; 95(1):88-95. PubMed ID: 22379747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.
    Hameed O; Adams AL; Baker AC; Balmer NE; Bell WC; Burford HN; Chhieng DC; Jhala NC; Klein MJ; Winokur T
    Am J Clin Pathol; 2008 Sep; 130(3):425-7. PubMed ID: 18701416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
    Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
    Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies.
    Tapia C; Schraml P; Simon R; Al-Kuraya KS; Maurer R; Mirlacher M; Novotny H; Spichtin H; Mihatsch MJ; Sauter G
    Int J Oncol; 2004 Dec; 25(6):1551-7. PubMed ID: 15547690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer.
    Bahreini F; Soltanian AR; Mehdipour P
    Breast Cancer; 2015 Nov; 22(6):615-25. PubMed ID: 24718809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
    Hicks DG; Tubbs RR
    Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
    O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
    Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
    Green IF; Zynger DL
    Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India.
    Panjwani P; Epari S; Karpate A; Shirsat H; Rajsekharan P; Basak R; Shet T; Chinoy R; Chacko R; Gursale S; Baraskar N; Gupta S; Hawaldar R; Desai S
    Indian J Med Res; 2010 Sep; 132():287-94. PubMed ID: 20847375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.
    Lehr HA; Jacobs TW; Yaziji H; Schnitt SJ; Gown AM
    Am J Clin Pathol; 2001 Jun; 115(6):814-22. PubMed ID: 11392876
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
    Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
    Gao FF; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing HER2 assessment in breast cancer: application of automated image analysis.
    Holten-Rossing H; Møller Talman ML; Kristensson M; Vainer B
    Breast Cancer Res Treat; 2015 Jul; 152(2):367-75. PubMed ID: 26109345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
    Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
    Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer.
    Moon YW; Jeung HC; Rha SY; Choi YH; Yang WI; Chung HC
    Breast Cancer Res Treat; 2007 Jul; 104(1):31-7. PubMed ID: 17587181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
    Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
    Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.